Page last updated: 2024-12-06

inaperisone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Inaperisone is a drug that is being investigated for its potential to treat various neurological disorders, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and Huntington's disease. Its mechanism of action is thought to involve the modulation of neurotransmitter release and the protection of neurons from damage. Inaperisone was initially developed as a muscle relaxant, but its potential benefits in neurological disorders have sparked significant interest. Preclinical studies have shown promising results, suggesting that inaperisone may improve motor function and reduce disease progression. The compound's ability to cross the blood-brain barrier and its favorable safety profile have made it an attractive candidate for further research. Inaperisone is currently in clinical trials to evaluate its efficacy and safety in humans. While further research is needed, inaperisone holds promise as a potential treatment for a range of neurological disorders.'

inaperisone: structure given in first source; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65860
CHEMBL ID1797127
CHEBI ID134999
SCHEMBL ID250427
MeSH IDM0148848

Synonyms (21)

Synonym
inaperisone
CHEBI:134999
1-(4-ethylphenyl)-2-methyl-3-pyrrolidin-1-ylpropan-1-one
CHEMBL1797127
99323-21-4
inaperisonum [inn-latin]
inaperisona [inn-spanish]
inaperisone [inn]
1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pyrrolidinyl)-,
unii-0qac3p785o
(+-)-4'-ethyl-2-methyl-3-(1-pyrrolidinyl)propiophenone
0qac3p785o ,
inaperisona
inaperisonum
inaperisone [mi]
(+/-)-4'-ethyl-2-methyl-3-(1-pyrrolidinyl)propiophenone
SCHEMBL250427
(+/-)-inaperisone
DTXSID60869332
Q15519876
1-propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-pyrrolidinyl)-

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Taken all together, we developed a physiologically-based pharmacokinetic model of IPS combined with its pharmacological effect in rats, which could simulate the concentration-dependent changes in blood flow rates based on the drug concentrations at the site of action."( Physiological pharmacokinetics of a new muscle-relaxant, inaperisone, combined with its pharmacological effect on blood flow rate.
Kato, H; Murata, M; Nagata, O; Sato, H; Terasaki, T; Tsuji, A,
)
0.38

Compound-Compound Interactions

ExcerptReferenceRelevance
" Taken all together, we developed a physiologically-based pharmacokinetic model of IPS combined with its pharmacological effect in rats, which could simulate the concentration-dependent changes in blood flow rates based on the drug concentrations at the site of action."( Physiological pharmacokinetics of a new muscle-relaxant, inaperisone, combined with its pharmacological effect on blood flow rate.
Kato, H; Murata, M; Nagata, O; Sato, H; Terasaki, T; Tsuji, A,
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's2 (20.00)18.2507
2000's2 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.61 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]